106 related articles for article (PubMed ID: 22672803)
1. Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3β inhibitors.
Lee SC; Kim HT; Park CH; Lee DY; Chang HJ; Park S; Cho JM; Ro S; Suh YG
Bioorg Med Chem Lett; 2012 Jul; 22(13):4221-4. PubMed ID: 22672803
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 2-(4-(methylsulfonyl)phenyl)pyridine derivatives as GPR119 agonists.
Zhou Y; Zhu X; Zhang L; Tang C; Feng B
Chem Biol Drug Des; 2019 Jan; 93(1):67-74. PubMed ID: 30120879
[TBL] [Abstract][Full Text] [Related]
3. Novel nanomolar imidazo[4,5-b]pyridines as selective nitric oxide synthase (iNOS) inhibitors: SAR and structural insights.
Grädler U; Fuchss T; Ulrich WR; Boer R; Strub A; Hesslinger C; Anézo C; Diederichs K; Zaliani A
Bioorg Med Chem Lett; 2011 Jul; 21(14):4228-32. PubMed ID: 21684157
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes.
Crane L; Anastassiadou M; El Hage S; Stigliani JL; Baziard-Mouysset G; Payard M; Leger JM; Bizot-Espiard JG; Ktorza A; Caignard DH; Renard P
Bioorg Med Chem; 2006 Nov; 14(22):7419-33. PubMed ID: 16889967
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
6. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.
Lin H; Yamashita DS; Xie R; Zeng J; Wang W; Leber J; Safonov IG; Verma S; Li M; Lafrance L; Venslavsky J; Takata D; Luengo JI; Kahana JA; Zhang S; Robell KA; Levy D; Kumar R; Choudhry AE; Schaber M; Lai Z; Brown BS; Donovan BT; Minthorn EA; Brown KK; Heerding DA
Bioorg Med Chem Lett; 2010 Jan; 20(2):684-8. PubMed ID: 20006500
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C
J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540
[TBL] [Abstract][Full Text] [Related]
8. The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
Pfefferkorn JA; Tu M; Filipski KJ; Guzman-Perez A; Bian J; Aspnes GE; Sammons MF; Song W; Li JC; Jones CS; Patel L; Rasmusson T; Zeng D; Karki K; Hamilton M; Hank R; Atkinson K; Litchfield J; Aiello R; Baker L; Barucci N; Bourassa P; Bourbonais F; D'Aquila T; Derksen DR; MacDougall M; Robertson A
Bioorg Med Chem Lett; 2012 Dec; 22(23):7100-5. PubMed ID: 23089526
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Shin D; Lee SC; Heo YS; Lee WY; Cho YS; Kim YE; Hyun YL; Cho JM; Lee YS; Ro S
Bioorg Med Chem Lett; 2007 Oct; 17(20):5686-9. PubMed ID: 17764934
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.
Meegalla SK; Huang H; Illig CR; Parks DJ; Chen J; Lee YK; Wilson KJ; Patel SK; Cheung WS; Lu T; Kirchner T; Askari HB; Geisler J; Patch RJ; Gibbs AC; Rady B; Connelly M; Player MR
Bioorg Med Chem Lett; 2016 Sep; 26(17):4216-22. PubMed ID: 27491708
[TBL] [Abstract][Full Text] [Related]
11. Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.
Peterson EA; Boezio AA; Andrews PS; Boezio CM; Bush TL; Cheng AC; Choquette D; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Kim JL; Lewis RT; Liu J; Mullady EL; Potashman MH; Romero K; Shaffer PL; Stanton MK; Stellwagen JC; Teffera Y; Yi S; Cai T; La DS
Bioorg Med Chem Lett; 2012 Aug; 22(15):4967-74. PubMed ID: 22765895
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
Meng W; Brigance RP; Chao HJ; Fura A; Harrity T; Marcinkeviciene J; O'Connor SP; Tamura JK; Xie D; Zhang Y; Klei HE; Kish K; Weigelt CA; Turdi H; Wang A; Zahler R; Kirby MS; Hamann LG
J Med Chem; 2010 Aug; 53(15):5620-8. PubMed ID: 20684603
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
[TBL] [Abstract][Full Text] [Related]
15. Discovery, synthesis and in combo studies of a tetrazole analogue of clofibric acid as a potent hypoglycemic agent.
Navarrete-Vázquez G; Alaniz-Palacios A; Hidalgo-Figueroa S; González-Acevedo C; Ávila-Villarreal G; Estrada-Soto S; Webster SP; Medina-Franco JL; López-Vallejo F; Guerrero-Álvarez J; Tlahuext H
Bioorg Med Chem Lett; 2013 Jun; 23(11):3244-7. PubMed ID: 23597793
[TBL] [Abstract][Full Text] [Related]
16. Imidazopyridyl compounds as aldosterone synthase inhibitors.
Whitehead BR; Lo MM; Ali A; Park MK; Hoyt SB; Xiong Y; Cai J; Carswell E; Cooke A; MacLean J; Ratcliffe P; Robinson J; Bennett DJ; Clemas JA; Wisniewski T; Struthers M; Cully D; MacNeil DJ
Bioorg Med Chem Lett; 2017 Jan; 27(2):143-146. PubMed ID: 27979595
[TBL] [Abstract][Full Text] [Related]
17. Anti-diabetic efficacy of KICG1338, a novel glycogen synthase kinase-3β inhibitor, and its molecular characterization in animal models of type 2 diabetes and insulin resistance.
Kim KM; Lee KS; Lee GY; Jin H; Durrance ES; Park HS; Choi SH; Park KS; Kim YB; Jang HC; Lim S
Mol Cell Endocrinol; 2015 Jul; 409():1-10. PubMed ID: 25802191
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel peptide MC62 analogues as potential antihyperglycemic agents.
Yang B; Mei Y; Wang X; Deng X; Qian H; Huang W
Eur J Med Chem; 2014 Feb; 73():105-11. PubMed ID: 24384551
[TBL] [Abstract][Full Text] [Related]
19. Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Lee J; Kim H; Yu H; Chung JY; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Mar; 20(5):1573-7. PubMed ID: 20149658
[TBL] [Abstract][Full Text] [Related]
20. IRAK-4 inhibitors. Part II: a structure-based assessment of imidazo[1,2-a]pyridine binding.
Buckley GM; Ceska TA; Fraser JL; Gowers L; Groom CR; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V
Bioorg Med Chem Lett; 2008 Jun; 18(11):3291-5. PubMed ID: 18482836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
